Taking Direction from Industry Veterans

Icon_Moon.svg The Road to BIO: Day 7

Wednesday, June 14, 2017
Mississippi /// Texas
Featured Sponsor: Avara Pharmaceutical Services

 


Delivering on Commitments 

Avara Pharmaceutical Services was founded by a team of industry veterans who, through personal experience, understand both sides of the contract manufacturing market. We know what developers’ expectations are, and we know the pitfalls and typical areas of frustration. We therefore built a CDMO that is focused on delivering exceptional service and a world-class experience.

Supporting Biotechs in Advancing Their Molecules

Different types of companies face different challenges depending on their own capabilities, but some of the core pressures are common to the industry. There is a demand for therapies that will improve patients’ lives and a business case for being early to market. However, safety and efficacy remain fundamental of course. The complexity of many new compounds can intensify these challenges, so the outsourcing market that continues to grow around today’s biopharmaceutical development has to be ever more sophisticated, while remaining entirely reliable. . 

A Quality Partner

Research shows that the key things developers are looking for from CDMO partnerships are quality and reliability. They need a CDMO to deliver on what is committed in terms of scope, schedule, quantities and price. However, they’re also looking for a partner that they feel listens to them, offers flexibility and agility that serves their needs, and is transparent in communication. All of these things contribute to integrity, and they are part of a commitment that Avara makes to every client. 

Navigating Adversity in Biopharmaceutical Development

One of the most significant differences in the success and speed of biopharmaceutical development is avoiding and navigating pitfalls. The ability to overcome inevitable problems, stay on schedule especially in trials, deliver each stage to agreed objectives, and stay on budget is significantly boosted by the experience of having ‘been there before’. Avara’s leadership team has extensive knowledge on both sides of the CDMO business and experience commercializing hundreds of compounds. The project benefit and reassurance in this level of expertise is immeasurable.

Meeting Trend-Driven Needs 

There has been a long-term trend towards outsourcing that is projected to continue into the next decade, as the major biopharmaceutical companies consolidate their own manufacturing footprints and increasingly work with reliable and efficient contract service providers. Avara Pharmaceutical Services was established through the acquisition of world-class facilities from leading pharmaceutical companies, which is one aspect of our strategic positioning to meet trend-driven needs. We will continue with this acquisition strategy and, combined with the experience of our leadership and expertise across our entire staff, we will fulfill the Avara Promise to provide a customer-oriented outsourcing experience and unwaveringly deliver on our commitments in terms of scope, schedule, quality, and price. 



Avara.png 

About Avara Pharmaceutical Services 

Avara is a global CDMO set up specifically to focus on clients’ priorities and provide an exceptional outsourcing experience by delivering on our commitments. Led by a team of highly experienced industry veterans who have been on both sides of outsourcing, we fully understand the challenges you face, and offer the flexibility to perfectly align with your needs. 


 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: